Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of [14C] Yiqibuvir in Healthy Male Participants
NCT05998304Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Aug 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of encofosbuvir in hepatitis C (HCV), sponsored by Sunshine Lake Pharma. Primary endpoint: Cumulative excretion of [14C] Yiqibuvir-related material up to 18 days. Started Aug 2023; status: completed.
02
Drugs
encofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05998304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05998304.